Drugs / F01
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06468683 | Jun 2024 → Jan 2027 expected | systemic lupus erythematosus | Shanghai Simnova Biotechnology Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06206902 | Apr 2024 → Jan 2025 | non-Hodgkin lymphoma | Shanghai Simnova Biotechnology Co.,Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06208280 | Jan 2024 → Jan 2025 | autoimmune disease | RenJi Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06468683 ↗ |
| Modality | Cell therapy | “Biological: 0.5-3×10\^9 CAR+NK Cells” NCT06206902 ↗ |